In conclusion, the combination of the STING agonist and RG3 effectively reversed cisplatin resistance in gastric cancer, enhanced the cisplatin sensitivity of SGC‐7901/DDP cells during tumor growth, and inhibited tumor progression. Here, STING1 is linked to neoplasm.